Custom enzymes,
strains, and processes
for practical
biomanufacturing

Evolutia Bio develops proprietary biomanufacturing solutions for pharma, industrial and ingredient partners. Combined with Mycofeast’s scale-up and manufacturing capabilities as well as AI-accelerated workflows, we provide a more complete path from concept to commercial production.

Formerly Willow Biosciences / Epimeron Inc, acquired by Mycofeast in 2025

What We Do

Built around commercial
outcomes, not just discovery

Evolutia Bio leverages AI-guided design and engineering to develop custom enzymes, engineered strains, and biomanufacturing processes for partners seeking more efficient, scalable, and commercially viable production routes.

Custom Enzymes

Design and optimize custom enzymes for therapeutic and industrial applications, enabling challenging chemical transformations through AI-guided sequence diversification and recombination. Our AI-driven enzyme engineering platform leverages eight years of experimental data generated through collaborative research programs.

Strain Engineering

Improve production hosts for better titer, robustness, and product profile through genome-wide engineering approaches.

Process Development

Build practical and AI-integrated development workflows from screening through fermentation, downstream optimization, and scale-up readiness.

Industries

Food & Ingredients

Functional ingredients, specialty molecules, fermentation-enabled products.

Agriculture

Biobased processes for active ingredients and performance-enhancing compounds.

Pharma

Enzyme and strain engineering for therapeutics, pharmaceutical intermediates, and complex biocatalytic transformations.

Fine chemicals

Custom enzymes and biobased processes for efficient, scalable production of specialty and high-value chemicals.

Industrial Biomanufacturing

Commercially relevant process design where biology creates a better route.

EVOLUTIA × MYCOFEAST

A more complete route from development to production

In biomanufacturing, one of the hardest steps is turning a promising lab result into a process that can scale and stand up commercially.

Evolutia and Mycofeast work together to tackle that challenge by turning novel biology into scalable biomanufacturing processes that perform beyond the lab.

EVOLUTIA BIO

AI-enabled enzyme engineering · Genome-wide strain improvement · High-throughput screening · Fermentation & downstream development · BioOxi™ oxidation platform

↕ DEVELOPMENT → MANUFACTURING ↕

MYCOFEAST

Bench-to-pilot-to-plant translation · Industrial fermentation know-how · Production infrastructure ·
Scale-up and commercial deployment

Team

The team behind the platform

CHRIS Davis

Managing Director

JASON Lewis

Managing Director

VESNA Mitchell

Senior Director, Genetic Engineering